Trial · NCT02883556
Study of Pembrolizumab as First Line Therapy in Patients With Unresectable Squamous Cell Carcinoma of the Skin
NCT02883556, Phase 2, Completed, Assistance Publique - Hôpitaux de Paris
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Study of Pembrolizumab as First Line Therapy in Patients With Unresectable Squamous Cell Carcinoma of the Skin. Trials, record NCT02883556. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02883556
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Study of Pembrolizumab as First Line Therapy in Patients With Unresectable Squamous Cell Carcinoma of the Skin
- NCT number
- NCT02883556
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 57 participants, actual
- Lead sponsor
- Assistance Publique - Hôpitaux de Paris
- Conditions
- Carcinoma, Squamous Cell
- Interventions
- Pembrolizumab
- First posted
- 2016-08-30
- Last updated
- 2021-01-13
- Other registries' IDs
- eudract:2016-002076-28
Source ClinicalTrials.gov
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Response rate (RR) | 15 weeks | Response rate (RR) at 15 weeks (RECIST v.1.1) in the whole sample by CT or MRI Response Evaluation Criteria in Solid Tumors with central radiology review |
| Secondary | Safety profile (NCI CTCAE v4.0) | up to 28 months | Advers event and serious adverse event status |
| Secondary | RR in PD-L1-positive patients | 15 weeks | To assess in the whole sample and in PD-L1 positive patients |
| Secondary | Disease Control Rate using RECIST and modified RECIST v.1.1 | 15 weeks | Controled by the radiological evaluation |
| Secondary | RR using modified RECIST 1.1 | 15 weeks | Controled by the radiological evaluation |
| Secondary | RR using RECIST and modified RECIST v.1.1 | 24 weeks | Controled by the radiological evaluation |
| Secondary | Best RR using RECIST and modified RECIST v.1.1 | 24 months | The best response was collected after all radiological evaluation completion |
| Secondary | Overall Survival (OS) | up to 24 months | Survival status |
| Secondary | Progression Free Survival by RECIST 1.1 and modified RECIST 1.1 | up to 24 months | Controled by the radiological evaluation |
| Secondary | Duration of response (DOR) by RECIST 1.1 and modified RECIST 1.1 | up to 24 months | Controled by the radiological evaluation |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 32730186 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02883556
GET https://conductscience.org/api/trials/v1/NCT02883556/registered